ZBH Q4 2025 Earnings Call Summary | Stock Taper
Logo
Pricing Log In
ZBH

ZBH — Zimmer Biomet Holdings, Inc.

NYSE

Q4 2025 Earnings Call Summary

February 10, 2026

Summary of Zimmer Biomet (ZBH) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

  • Q4 2025 Performance:

    • Organic constant currency sales growth of 5.4%.
    • U.S. business grew 5.7%, while international sales increased 5%.
    • Adjusted EPS of $2.42, up 4.8% year-over-year.
    • Full-year adjusted EPS for 2025 was $8.20.
    • Free cash flow reached $1.172 billion, marking an 11% year-over-year growth.

  • Revenue:

    • Q4 net sales were $2.244 billion, a 10.9% increase on a reported basis.
    • Consolidated pricing was down 50 basis points in Q4.

2. Strategic Updates and Business Highlights

  • Sales Channel Transformation:

    • Zimmer Biomet is transitioning to a dedicated U.S. sales force to enhance specialization, aiming for completion by 2027.
    • The strategy includes adding over 200 sales reps in high-growth areas like robotics and ambulatory surgical centers (ASCs).

  • Product Innovation:

    • Successful launches of new products, including the Oxford Partial Cementless Knee and Z1 triple taper stem, contributed to growth.
    • The Direct to Patient Awareness Campaign featuring Arnold Schwarzenegger boosted engagement and sales.

  • Operational Excellence:

    • Continued focus on cost management and capital allocation to enhance EPS growth and free cash flow.

3. Forward Guidance and Outlook

  • 2026 Expectations:
    • Projected organic constant currency revenue growth of 1% to 3%.
    • Adjusted EPS guidance of $8.30 to $8.45.
    • Anticipated free cash flow growth of 8% to 10%.
    • The guidance reflects potential disruption from the sales force transition and a stable tariff environment.

4. Bad News, Challenges, or Points of Concern

  • Sales Force Transition Risks:

    • The ongoing transformation may lead to short-term disruptions affecting sales performance, particularly in the first half of 2026.

  • Pricing Pressure:

    • Expected pricing erosion of up to 100 basis points in 2026 due to competitive pressures and market conditions.

  • International Market Fragility:

    • International sales performance has been inconsistent, with concerns about growth in key geographies.

  • Integration Challenges:

    • The integration of the Paragon 28 acquisition has shown some delays in expected revenue contributions, with a commitment to achieve double-digit growth in 2026.

5. Notable Q&A Insights

  • Sales Force Transition:

    • CEO Ivan Tornos emphasized the importance of specialization and the need for a dedicated sales force to improve productivity, which is currently lagging compared to competitors.

  • Market Conditions:

    • Executives acknowledged the potential for disruption during the sales force transition but expressed confidence in the long-term benefits of the strategy.

  • Product Launches:

    • There was excitement around the upcoming launch of the mBOS robotic system, which is expected to significantly enhance the company's offerings in robotics.

  • Capital Allocation Strategy:

    • The focus will shift towards returning cash to shareholders through buybacks rather than pursuing new acquisitions, with a buyback program of up to $1.5 billion approved.

This summary encapsulates the key points from the earnings call, highlighting both the achievements and challenges facing Zimmer Biomet as it moves into 2026.

← Q3 2025